Table 2.
Clinical effects of Kampo medicine on chemotherapy-induced adverse effects for gastrointestinal cancer
| Author (year) | Type of Cancer | Study medicine | Primary endpoint | Sample size | Results |
|---|---|---|---|---|---|
| Matsuda (2015) | Colorectal cancer | Hangeshashinto (TJ-14) | Incidence of chemotherapy-induced oral mucositis (COM) | TJ-14,n=43 Placebo, n=47 |
COM was 48.8% in TJ-14 and 57.4% in placebo |
| Aoyama (2014) | Gastric cancer | Hangeshashinto (TJ-14) | Incidence of chemotherapy-induced oral mucositis (COM) | TJ-14,n=45 Placebo, n=46 |
COM was 40.0% in TJ-14 and 41.3% in placebo |
| Kono (2013) |
Colorectal cancer | Goshajinkigan (TJ-107) | Incidence of oxaliplatin-induced peripheral neurotoxicity (OPN) | TJ-107, n=44 Placebo, n=45 |
OPN was 39% in TJ-14 and 51% in placebo |
| Oki (2015) |
Colorectal cancer | Goshajinkigan (TJ-107) | Incidence of oxaliplatin-induced peripheral neurotoxicity (OPN) | TJ-107, n=89 Placebo, n=93 |
OPN was 50.6% in TJ-14 and 31.2% in placebo |